A novel coronavirus drug  Azvudine is effective in treating novel coronavirus pneumonia.

Azvudine (azvudine, referred to as FNC) class 1.1 new drug is the first international anti HIV dual target innovative drug jointly developed by Henan real Biotechnology Co., Ltd., Zhengzhou University, Henan Normal University and the high tech research center of Henan Academy of Sciences. Compared with the listed nucleoside reverse transcriptase inhibitors, FNC has unique advantages Special mechanism and strong function of inhibiting virus replication. It has applied for patents and obtained authorization in China, the United States, Europe and other countries all over the world. According to the results of previous studies, FNC has the effect of broad-spectrum inhibition of RNA virus replication, and has good clinical safety.

国产新药阿兹夫定治疗新冠肺炎效果显著 郑州中院特聘技术专家为抗疫作出新贡献

阿兹夫定（Azvudine，简称FNC）1.1类新药是由国家重大新药专项支持、常俊标教授发明、河南真实生物科技有限公司、郑州大学、河南师范大学、河南省科学院高新技术研究中心共同研发的国际上首个抗HIV双靶点创新药物，与已上市的核苷类逆转录酶***相比较，FNC具有独特作用机制和很强抑制病毒复制的功能。已在中国、美国、欧洲等全球范围申请了专利并获得授权。根据前期研究结果表明：FNC具有广谱抑制RNA病毒复制的作用，并且临床安全性良好。